Baveno VI标准在HCC患者中验证及SAPHE-R新策略开发
在598例BCLC 0-C期HCC合并cACLD患者中验证Baveno VI标准,发现其遗漏8.5%的静脉曲张和6.0%的高危静脉曲张,仅节省31.1%的内镜。基于LSM≤16 kPa、血小板≥160×10⁹/L和ALBI 1级构建的SAPHE-R规则遗漏4.0%的静脉曲张,节省17.6%内镜,并在149例外部验证队列中表现一致。
要点
- Baveno VI标准在HCC合并cACLD患者中遗漏8.5%的静脉曲张和6.0%的高危静脉曲张。
- SAPHE-R规则(LSM≤16 kPa、血小板≥160×10⁹/L、ALBI 1级)遗漏4.0%的静脉曲张。
- SAPHE-R在外部验证队列中遗漏4.8%的静脉曲张,节省14.8%的内镜。
核心结论
- Baveno VI标准在HCC合并cACLD患者中表现欠佳,而SAPHE-R提供了可靠的非侵入性策略以排除静脉曲张。
研究设计与样本
- 多中心回顾性队列研究,推导队列来自意大利肝癌数据库共598例BCLC 0-C期HCC合并cACLD患者,独立验证队列来自维也纳共149例。
主要发现
- 推导队列中静脉曲张患病率33.4%,高危静脉曲张11.2%。
- Baveno VI标准遗漏8.5%的静脉曲张和6.0%的高危静脉曲张,节省31.1%的上消化道内镜。
- SAPHE-R规则遗漏4.0%的静脉曲张(高危静脉曲张3.0%),节省17.6%的上消化道内镜。
- 验证队列中SAPHE-R遗漏4.8%的静脉曲张(高危静脉曲张3.1%),节省14.8%的上消化道内镜。
- 探索性分析中,SAPHE-R排除组未观察到HVPG定义的重度门脉高压(0/22)。
关键数值与推荐
- SAPHE-R规则:LSM≤16 kPa、血小板≥160×10⁹/L、ALBI 1级可排除静脉曲张。
临床怎么用
- 对BCLC 0-C期HCC合并cACLD患者,SAPHE-R可用于排除静脉曲张以减少不必要的内镜。
- Baveno VI标准在该人群中遗漏率较高,应用时需谨慎。
局限性
- 推导队列为回顾性数据库分析,可能存在选择偏倚。
- 验证队列样本量较小(n=149)。
- 探索性HVPG分析样本量极小(n=22)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Accuracy of Baveno criteria for avoiding endoscopy in patients with hepatocellular carcinoma (HCC) is uncertain, and systematic upper gastrointestinal endoscopy (UGE) may not be necessary. We evaluated Baveno VI criteria performance in this population and developed an alternative non-invasive rule to exclude esophagogastric varices of any grade, rather than high-risk varices (HRV). METHODS: Patients with BCLC 0-C HCC and compensated advanced chronic liver disease (cACLD) from Italian Liver Cancer (ITA.LI.CA) database, with available liver stiffness measurement (LSM), UGE, and blood tests within six months of diagnosis, were included. Independent predictors of varices identified by logistic regression were combined through grid-search to derive a rule-out strategy (SAPHE-R), validated by bootstrap-resampling and in an independent cohort (Vienna). RESULTS: The derivation cohort comprised 598 patients (age, 69 years; male sex, 75.3%; viral etiology, 69.3%; BCLC 0/A, 77.9%; ALBI 1, 54.2%; varices, 33.4%; HRV, 11.2%). Baveno VI criteria missed 8.5% of varices and 6.0% of HRV, sparing 31.1% of UGE. Independent predictors of varices were incorporated into SAPHE-R (LSM≤16 kPa, platelet count ≥160×10⁹/L, ALBI grade 1), which missed 4.0% of varices (HRV 3.0%, spared UGE 17.6%). In the validation cohort (n=149), SAPHE-R missed 4.8% of varices (HRV 3.1%, spared UGE 14.8%). Results remained consistent in sensitivity analyses. In an exploratory analysis, no HVPG-defined CSPH was observed among SAPHE-R rule-out patients (0/22). CONCLUSIONS: Baveno VI criteria showed suboptimal performance in patients with HCC and cACLD, whereas SAPHE-R provided a reliable non-invasive strategy to rule out varices, facilitating variceal risk assessment in patients with HCC.
引用
- Argiento L, Canova L, Alimenti E, et al. Baveno VI criteria validation and development of a new non-invasive strategy for varices rule-out in patients with HCC (SAPHE-R: Stiffness, ALBI, Platelets, HEpatocellular carcinoma Rule). Hepatology. 2026. PMID: 42911124. doi:10.1097/HEP.0000000000001893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。